News

Initial investment in Avelo

OCCIDENT further strengthens its portfolio in the field of diagnostics and leads Avelo’s oversubscribed 2.2 million seed financing round.

The Zurich-based diagnostics startup develops a simple breath collector to improve the diagnosis of tuberculosis and other respiratory infections that cause pneumonia – the fourth leading cause of death worldwide. Physicians will be able to use this non-invasive sampling tool to painlessly collect a patient’s breath sample from the respiratory tract, particularly from the lower respiratory tract, and analyze it with existing PCR testing infrastructure for fast and accurate diagnosis.

More information in the press release under the following Link

More about Avelo

Initial investment in core sensing Overview Successful Exit Versantis
Want to learn more about OCCIDENT?

News

About

New OCCIDENT Website

Having sharpened our investor profile and revised our communi­cation, we get to the point: OCCIDENT – The Science Investor.